Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of indacaterol + glycopyrronium on nocturnal oxygen saturation in COPD
2013-005573-51Phase 4Completed
- Sponsor
- Novartis
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of indacaterol and glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Primary endpoint: Mean night-time oxygen hemoglobin saturation level. Started Jun 2014; status: completed.
02
Drugs
indacaterolglycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2013-005573-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005573-51.